PSADT | |||
---|---|---|---|
PSADT > 6 | PSADT < 6 | p-value | |
(n=176) | (n=101) | ||
Age Median (IQR) | 65.5 (59.4-70.2) | 62.8 (58.6-68.6) | p=0.14* |
CCMI Median (IQR) | 3.0 (3.0-4.0) | 3.0 (3.0-4.0) | p=0.2* |
Range | 1.0-8.0 | 1.0-7.0 | |
Pre-SRT PSA Median (IQR) | 0.6 (0.4-1.1) | 0.8 (0.5-1.75) | p<0.001* |
Range | 0.1-6.3 | 0.2-17.4 | |
SRT dose Median (IQR) | 68.4 (64.8-68.4) | 68.4 (64.8-68.4) | p=0.05* |
WPRT | 11.4% | 6.9% | p=0.3** |
ADT during SRT | 12.5% | 18.8% | p=0.2** |
ADT duration | 5.9 (4.4-8.5) | 6.1 (4.7-15.1) | p=0.6* |
Gleason score | |||
2-6 | 22.2% | 11.9% | p=0.02** |
7 | 61.4% | 60.4% | |
8-10 | 16.5% | 27.7% | |
pTstage | |||
T1-T2a | 13.0% | 6.3% | p=0.15** |
T2b-T2c | 32.2% | 27.5% | |
T3-T4 | 54.8% | 66.3% | |
SVI | 9.8% | 16.8% | p=0.13** |
ECE | 45.4% | 52.5% | p=0.3** |
SM | 43.2% | 44.0% | p=0.9** |
LNI | 2.1% | 1.2% | p=0.9** |